These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43 related articles for article (PubMed ID: 13651284)
1. [Comparative studies on serological properties of anti-cancer horse serum fractions]. NAZARENKO NA; GOSTEV VS Biull Eksp Biol Med; 1959 Mar; 47(3):70-5. PubMed ID: 13651284 [No Abstract] [Full Text] [Related]
2. [Comparative studies on the antigenic structure of tumor and homologous normal tissues. I. Studies on antigenic properties of Gueren's carcinoma and of normal rat uterus using complement fixation reaction]. LOMAKIN MS Biull Eksp Biol Med; 1959 May; 47(5):91-5. PubMed ID: 13671048 [No Abstract] [Full Text] [Related]
4. [Complement fixation reaction with human blood coagulum extract investigated with the aid of the blood serum of cancer patients]. RAVKINA LI Vopr Onkol; 1960; 6(11)():70-4. PubMed ID: 13739917 [No Abstract] [Full Text] [Related]
5. [Serological reaction used in the physiopathological study of neoplasms. VI. Isolation of the serologically-active fraction]. Marzona M; Dovis M; Chiesa D; Molfese G; Biarese V; Lovisetto P Boll Soc Ital Biol Sper; 1977 May; 53(9):706-9. PubMed ID: 911520 [No Abstract] [Full Text] [Related]
6. [Antibody and complement functions in cancer]. DITTMAR F Hippokrates; 1958 Jul; 29(13):403-5. PubMed ID: 13574701 [No Abstract] [Full Text] [Related]
7. Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development. Gancz D; Fishelson Z Mol Immunol; 2009 Sep; 46(14):2794-800. PubMed ID: 19501402 [TBL] [Abstract][Full Text] [Related]
8. [Prolonged heterologous transplantation of mouse tumor to rats. II. Complement fixation reaction in the study of antigenic properties of Ehrlich ascites carcinoma in heterotransplantation]. PODOPLELOV II Biull Eksp Biol Med; 1959 Jan; 47(1):52-6. PubMed ID: 13638288 [No Abstract] [Full Text] [Related]
9. Cancer exploiting complement: a clue or an exception? Loveland BE; Cebon J Nat Immunol; 2008 Nov; 9(11):1205-6. PubMed ID: 18936777 [No Abstract] [Full Text] [Related]
10. Complement as effector system in cancer immunotherapy. Macor P; Tedesco F Immunol Lett; 2007 Jul; 111(1):6-13. PubMed ID: 17572509 [TBL] [Abstract][Full Text] [Related]
11. [Modifications of serological properties of the tissue in the presence of heterologus serum]. SUVOROVA GV Biull Eksp Biol Med; 1957 Jan; 43(1):82-5. PubMed ID: 13445875 [No Abstract] [Full Text] [Related]
12. Complement-mediated tumour growth: implications for cancer nanotechnology and nanomedicines. Moghimi SM; Andresen TL Mol Immunol; 2009 May; 46(8-9):1571-2. PubMed ID: 19286261 [TBL] [Abstract][Full Text] [Related]
13. Complement function in mAb-mediated cancer immunotherapy. Gelderman KA; Tomlinson S; Ross GD; Gorter A Trends Immunol; 2004 Mar; 25(3):158-64. PubMed ID: 15036044 [No Abstract] [Full Text] [Related]
14. Complement-fixation tests for antisera prepared against epithelial and fibroblast cell strains. MUSTAKALLIO E; GRONROOS JA Ann Med Exp Biol Fenn; 1961; 39():143-6. PubMed ID: 13727136 [No Abstract] [Full Text] [Related]
16. STUDIES ON THE IMMUNE GLOBULINS OF HUMAN SERUM. II. A STUDY OF THE DISTRIBUTION OF ANTI-BRUCELLA AND ANTI-DIPHTHERIA ANTIBODY ACTIVITIES AMONG GAMMA-SS, GAMMA-IM AND GAMMA-1A-GLOBULIN FRACTIONS. HEREMANS JF; VAERMAN JP; VAERMAN C J Immunol; 1963 Jul; 91():11-7. PubMed ID: 14061003 [No Abstract] [Full Text] [Related]
17. Role of heat-labile serum factor or host complement in the inhibition of Plasmodium falciparum sporogonic stages in Anopheles stephensi by gametocyte carriers' serological factors. Gouagna LC; van der Kolk M; Roeffen W; Verhave JP; Eling W; Sauerwein R; Boudin C Parasitology; 2007 Sep; 134(Pt 10):1315-27. PubMed ID: 17645813 [TBL] [Abstract][Full Text] [Related]
19. The preparation and properties of fractions of pig complement. II. LEON MA; PLESCIA OJ; HEIDELBERGER M J Immunol; 1955 Apr; 74(4):313-7. PubMed ID: 14367818 [No Abstract] [Full Text] [Related]
20. Cytotoxicity of a horse antihuman cancer serum for normal and malignant cells in vitro. GOLDSTEIN MN; HIRAMOTO R J Natl Cancer Inst; 1961 Sep; 27():487-501. PubMed ID: 13706672 [No Abstract] [Full Text] [Related] [Next] [New Search]